ReviewAngewandte Chemie (International ed. in English)2026
Advances in BODIPY Derivatives for Antibacterial Phototherapy.
Review in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The escalating threat posed by antibiotic-resistant bacteria and biofilm-associated infections has driven increasing interest in non-antibiotic antibacterial strategies. Antibacterial phototherapy (PT), including photodynamic therapy (PDT) and photothermal therapy (PTT), has attracted considerable attention owing to its spatiotemporal controllability, broad-spectrum antibacterial activity, and low propensity for inducing drug resistance. Boron-dipyrromethene (BODIPY) dyes, featuring exceptional structural tunability and favorable photophysical properties, have emerged as versatile scaffolds for the construction of antibacterial phototherapeutic systems. Through molecular engineering strategies including cationization, heavy-atom incorporation, and π-conjugation extension, combined with nanoassembly approaches, both the excited-state processes of BODIPY and its interactions with bacterial interfaces can be precisely regulated. Integration into diverse nanoplatforms further improves aqueous dispersibility, biological stability, and accumulation at bacterial or biofilm interfaces, thereby enhancing reactive oxygen species (ROS) generation or enabling photothermal effects to achieve PDT, PTT, or synergistic antibacterial therapy. This review systematically summarizes the design strategies and structure-activity relationships of BODIPY-based antibacterial phototherapy reported over the past five years, covering molecular engineering of small-molecule photosensitizers and nanoplatforms, bacterial targeting and carrier design, and discussing the challenges and future perspectives associated with clinical translation, particularly in terms of biosafety and targeted delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.